UBS Group AG Increases Stock Position in Palvella Therapeutics, Inc. $PVLA

UBS Group AG raised its holdings in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 78.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,505 shares of the company’s stock after purchasing an additional 16,066 shares during the quarter. UBS Group AG owned 0.31% of Palvella Therapeutics worth $3,821,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the business. Suvretta Capital Management LLC boosted its stake in shares of Palvella Therapeutics by 15.1% in the third quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock valued at $51,556,000 after buying an additional 107,937 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Palvella Therapeutics by 13.3% in the fourth quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after buying an additional 65,960 shares in the last quarter. First Light Asset Management LLC purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $33,949,000. Federated Hermes Inc. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $21,255,000. Finally, Millennium Management LLC purchased a new stake in shares of Palvella Therapeutics in the first quarter valued at approximately $7,553,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Stock Performance

PVLA opened at $113.99 on Friday. The business’s fifty day moving average is $121.93 and its two-hundred day moving average is $105.45. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -27.34 and a beta of -0.13. Palvella Therapeutics, Inc. has a one year low of $20.20 and a one year high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, analysts predict that Palvella Therapeutics, Inc. will post -5.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. BTIG Research lifted their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Mizuho lifted their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. Chardan Capital restated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research note on Thursday. Finally, Truist Financial set a $210.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $199.53.

Insiders Place Their Bets

In other news, Director Elaine J. Heron bought 2,400 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the director owned 47,812 shares in the company, valued at $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George M. Jenkins bought 4,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the transaction, the director owned 187,171 shares of the company’s stock, valued at $23,396,375. This represents a 2.18% increase in their position. The SEC filing for this purchase provides additional information. 20.50% of the stock is owned by company insiders.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.